Chen B, Yao W, Li X, Lin G, et al. A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer. Br J Cancer 2023 Dec 18. doi: 10.1038/s41416-023-02519.
PMID: 38110665